CD8A and neoplasm: Since the overall performance of the two binding assays appear to be sufficiently consistent, they could be used in a combinatorial manner to arrive at a selection of peptides that is subsequently used for pMHC-I multimer formation with the goal of identifying respective CD8+ T cell populations in peripheral blood or tumor infiltrates directly ex vivo, or after in vitro peptide restimulations.